Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...

Danish start-up Fuse Vectors has received $5.2 million in preseed financing to further develop their gene therapy technology. The company has developed a cell-free platform for producing ...

Gene therapy involves the introduction of foreign genomic materials into host cells to trigger clinical benefits. 1 Over the years, scientists have developed numerous viral and non-viral vectors to ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced ...

Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single ...

Gene therapy is a promising technique for the treatment of a wide range of diseases at the genetic level, addressing the root cause of many subsequent disorders. Recent advancements have facilitated ...

Opportunities in viral vector manufacturing arise from rising demand for GMP-grade materials and increasing gene therapy ...

DELRAY BEACH, FL / ACCESS Newswire / August 12, 2025 / Adolore BioTherapeutics, Inc., (“Company” or “Adolore”) announced that Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, ...

Importantly, no anti-drug antibodies (ADA) were detected in approximately 1,000 blood samples, addressing a key limitation of ...